

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

|      |    |        |  |
|------|----|--------|--|
| NEWS | 1  |        | Web Page for STN Seminar Schedule - N. America   |
| NEWS | 2  | AUG 06 | CAS REGISTRY enhanced with new experimental property tags  |
| NEWS | 3  | AUG 06 | FSTA enhanced with new thesaurus edition   |
| NEWS | 4  | AUG 13 | CA/CAPplus enhanced with additional kind codes for granted patents                               |
| NEWS | 5  | AUG 20 | CA/CAPplus enhanced with CAS indexing in pre-1907 records  |
| NEWS | 6  | AUG 27 | Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB |
| NEWS | 7  | AUG 27 | USPATOLD now available on STN  |
| NEWS | 8  | AUG 28 | CAS REGISTRY enhanced with additional experimental spectral property data                        |
| NEWS | 9  | SEP 07 | STN AnaVist, Version 2.0, now available with Derwent World Patents Index                         |
| NEWS | 10 | SEP 13 | FORIS renamed to SOFIS   |
| NEWS | 11 | SEP 13 | INPADOCDB enhanced with monthly SDI frequency  |
| NEWS | 12 | SEP 17 | CA/CAPplus enhanced with printed CA page images from 1967-1998                                   |
| NEWS | 13 | SEP 17 | CAPplus coverage extended to include traditional medicine patents                                |
| NEWS | 14 | SEP 24 | EMBASE, EMBAL, and LEMBASE reloaded with enhancements  |
| NEWS | 15 | OCT 02 | CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt                           |
| NEWS | 16 | OCT 19 | BEILSTEIN updated with new compounds   |
| NEWS | 17 | NOV 15 | Derwent Indian patent publication number format enhanced   |
| NEWS | 18 | NOV 19 | WPIX enhanced with XML display format  |
| NEWS | 19 | NOV 30 | ICSD reloaded with enhancements  |
| NEWS | 20 | DEC 04 | LINPADOCDB now available on STN  |
| NEWS | 21 | DEC 14 | BEILSTEIN pricing structure to change  |
| NEWS | 22 | DEC 17 | USPATOLD added to additional database clusters   |
| NEWS | 23 | DEC 17 | IMSDRUGCONF removed from database clusters and STN   |
| NEWS | 24 | DEC 17 | DGENE now includes more than 10 million sequences  |
| NEWS | 25 | DEC 17 | TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment                                  |
| NEWS | 26 | DEC 17 | MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary   |
| NEWS | 27 | DEC 17 | CA/CAPplus enhanced with new custom IPC display formats  |
| NEWS | 28 | DEC 17 | STN Viewer enhanced with full-text patent content from USPATOLD                                  |

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:21:21 ON 26 DEC 2007

=> file registry

| COST IN U.S. DOLLARS | SINCE FILE<br>ENTRY | TOTAL<br>SESSION |
|----------------------|---------------------|------------------|
| FULL ESTIMATED COST  | 0.42                | 0.42             |

FILE 'REGISTRY' ENTERED AT 13:22:18 ON 26 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 DEC 2007 HIGHEST RN 959463-53-7

DICTIONARY FILE UPDATES: 25 DEC 2007 HIGHEST RN 959463-53-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10 series\10526960\10526960a.str



```

chain nodes :
7 16 17 18 19 20 21 22 23 24 27 28
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13
chain bonds :
1-24 2-28 3-16 5-27 6-7 7-8 11-21 16-17 17-18 18-19 19-20 21-22 21-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
exact/norm bonds :
1-24 2-28 3-16 5-27 6-7 7-8 8-9 8-13 9-10 10-11 11-12 11-21 12-13
16-17 17-18 18-19 19-20 21-22 21-23
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

```

G1:N,CH

G2:X,O,CH3,H

G3:H,X

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:CLASS
22:CLASS 23:CLASS 24:CLASS 27:CLASS 28:CLASS


```

L1            STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1            STR



G1 N,CH

G2 X,O,Me,H

G3 H,X

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:23:20 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -        1157 TO ITERATE

100.0% PROCESSED        1157 ITERATIONS

5 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:    ONLINE    \*\*COMPLETE\*\*

BATCH    \*\*COMPLETE\*\*

PROJECTED ITERATIONS:        21100 TO        25180

PROJECTED ANSWERS:            5 TO            234


L2            5 SEA SSS SAM L1

=> d scan

L2    5 ANSWERS    REGISTRY    COPYRIGHT 2007 ACS on STN

IN    Pyrazinecarboxamide, 5-[2-fluoro-4-[[3-methylbutyl]amino]methyl]phenoxy]-  
      (9CI)


MF    C17 H21 F N4 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[3-(1-methylethoxy)propyl]amino]methyl]phenoxy]-  
 MF C20 H27 N3 O4  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN 2-Pyridinecarboxamide, 5-[2-methyl-4-[[[3-(1-methylethoxy)propyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI)  
 MF C19 H25 N3 O2 . C H4 O3 S  
 CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 full

FULL SEARCH INITIATED 13:23:39 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 23372 TO ITERATE

100.0% PROCESSED 23372 ITERATIONS

95 ANSWERS

SEARCH TIME: 00.00.01

L3 95 SEA SSS FUL L1


=> d scan

L3 95 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN


IN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[(3-methoxypropyl)amino]methyl]phen  
oxy]-, monomethanesulfonate (9CI)

MF C18 H23 N3 O4 . C H4 O3 S

CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

173.00

173.42

FILE 'CAPLUS' ENTERED AT 13:23:54 ON 26 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Dec 2007 VOL 147 ISS 26  
FILE LAST UPDATED: 25 Dec 2007 (20071225/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 3 L3

=> d l4 1-3 ibib abs hitstr

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:880769 CAPLUS

DOCUMENT NUMBER: 145:306599

TITLE: The  $\mu$ -opioid receptor subtype is required for the anorectic effect of an opioid receptor antagonist  
AUTHOR(S): Zhang, Jiaping; Frassetto, Andrea; Huang, Ruey-Ruey C.; Lao, Julie Z.; Pasternak, Alexander; Wang, Sheng-ping; Metzger, Joseph M.; Strack, Alison M.; Fong, Tung M.; Chen, Richard Z.

CORPORATE SOURCE: Department of Metabolic Disorders, Merck Research Laboratories, Rahway, NJ, 07065, USA

SOURCE: European Journal of Pharmacology (2006), 545(2-3), 147-152

CODEN: EJPHAZ; ISSN: 0014-2999

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A diaryl ether derivative, 6-(4-[(3-methylbutyl)amino]methyl]phenoxy)nicotina mide, was prepared and investigated for its biochem. properties at cloned opioid receptors and its pharmacol. effects on animal feeding. The compound displaced [3H]DAMGO binding of human  $\mu$ -opioid receptor, [3H]U-69593 of human  $\kappa$ -opioid receptor, and [3H]DPDPE of human  $\delta$ -opioid receptor with IC50 values of  $0.5 \pm 0.2$  nM,  $1.4 \pm 0.2$  nM, and  $71 \pm 15$  nM, resp. The compound also potently inhibited [3H]DAMGO binding of cloned mouse and rat  $\mu$ -opioid receptors ( $IC_{50} \approx 1$  nM), and acted as a competitive antagonist in a cAMP functional assay using cultured cells expressing human or mouse  $\mu$ -opioid receptors. Following a single oral administration in diet-induced obese mice (at 10 or 50 mg/kg) or rats (at 1, 3, or 10 mg/kg), the compound caused a dose-dependent suppression of acute food intake and body weight gain in both species. Importantly, the anorectic efficacy of the compound was mostly diminished in mice deficient in the  $\mu$ -opioid receptor. Our results suggest an important role for the  $\mu$ -opioid receptor subtype in animal feeding regulation and support the development of  $\mu$ -selective antagonists as potential agents for treating human obesity.

IT 676494-92-1, 6-(4-[(3-Methylbutyl)amino]methyl]phenoxy)nicotinami


de

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

( $\mu$ -opioid receptor subtype is required for anorectic effect of an opioid receptor antagonist)

RN 676494-92-1 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[ (3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:638874 CAPLUS

DOCUMENT NUMBER: 143:153386

TITLE: A preparation of di(hetero)aryl ethers, useful as opioid receptor antagonists

INVENTOR(S): De La Torre, Marta Garcia; Diaz Buezo, Nuria; Jadhav, Prabhakar Kondaji; Mitch, Charles Howard; Pedregal-Tercero, Concepcion

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO.  | DATE     |
|---|------|----------|------------------|----------|
| -----   | ---  | -----    | -----            | -----    |
| WO 2005066164   | A1   | 20050721 | WO 2004-US39766  | 20041215 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                  |          |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                  |          |
| AU 2004312312   | A1   | 20050721 | AU 2004-312312   | 20041215 |
| CA 2549089  | A1   | 20050721 | CA 2004-2549089  | 20041215 |
| EP 1699783  | A1   | 20060913 | EP 2004-812312   | 20041215 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS   |      |          |                  |          |
| CN 1894240  | A    | 20070110 | CN 2004-80037824 | 20041215 |
| BR 2004017714   | A    | 20070320 | BR 2004-17714    | 20041215 |
| JP 2007516284   | T    | 20070621 | JP 2006-547016   | 20041215 |
| US 2007112036   | A1   | 20070517 | US 2006-581178   | 20060531 |
| IN 2006DN03118  | A    | 20070824 | IN 2006-DN3118   | 20060531 |
| MX 2006PA07198  | A    | 20060904 | MX 2006-PA7198   | 20060622 |



PRIORITY APPLN. INFO.:

EP 2003-380303

A 20031222

US 2004-539748P

P 20040128



WO 2004-US39766

W 20041215

OTHER SOURCE(S):

CASREACT 143:153386; MARPAT 143:153386

GI



AB The invention relates to a preparation of di(hetero)aryl ethers, useful as opioid receptor antagonists. The invention compds. are useful for the treatment, prevention or amelioration of obesity and related diseases. For instance, phenoxynicotinamide derivative I [GTP- $\gamma$ -S binding assay,  $K_i$  (nM):  $\mu$  - 43.43,  $\kappa$  - 117.09,  $\delta$  - 269.06] was prepared via addition of hydroxylamine to phenoxynicotinonitrile derivative II with a yield

of

63%.


IT 676494-92-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of di(hetero)aryl ethers useful as opioid receptor antagonists)

RN 676494-92-1 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[[3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:267241 CAPLUS



DOCUMENT NUMBER: 140:303538

TITLE: Preparation of [[(aminoalkyl)aryl]oxy]nicotinamides and analogs as opioid receptor antagonist for treatment of obesity and related conditions

INVENTOR(S): Blanco-Pillado, Maria-Jesus; Chappell, Mark Donald; Garcia De la Torre, Marta; Diaz Buezo, Nuria; Fritz, James Erwin; Holloway, William Glen; Matt, James Edward, Jr.; Mitch, Charles Howard; Pedregal-Tercero, Concepcion; Quimby, Steven James; Siegel, Miles

PATENT ASSIGNEE(S): Eli Lilly and Company, USA  
SOURCE: PCT Int. Appl., 559 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE     | APPLICATION NO. | DATE       |
|------------------------|--|----------|-----------------|------------|
| WO 2004026305          | A1   | 20040401 | WO 2003-US26300 | 20030917   |
| WO 2004026305          | A9   | 20040513 |                 |            |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |          |                 |            |
| RW:                    | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                 |            |
| CA 2499690             | A1   | 20040401 | CA 2003-2499690 | 20030917   |
| AU 2003269980          | A1   | 20040408 | AU 2003-269980  | 20030917   |
| BR 2003014308          | A  | 20050705 | BR 2003-14308   | 20030917   |
| EP 1562595             | A1   | 20050817 | EP 2003-751877  | 20030917   |
| R:                     | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |          |                 |            |
| CN 1681498             | A  | 20051012 | CN 2003-822241  | 20030917   |
| JP 2006511474          | T  | 20060406 | JP 2004-537682  | 20030917   |
| US 2006217372          | A1   | 20060928 | US 2005-526960  | 20050303   |
| MX 2005PA03093         | A  | 20050713 | MX 2005-PA3093  | 20050318   |
| IN 2005KN00457         | A  | 20060303 | IN 2005-KN457   | 20050318   |
| NO 2005001871          | A  | 20050418 | NO 2005-1871    | 20050418   |
| PRIORITY APPLN. INFO.: |  |          | US 2002-412158P | P 20020919 |
|                        |  |          | WO 2003-US26300 | W 20030917 |
| OTHER SOURCE(S):       | MARPAT 140:303538  |          |                 |            |
| GI                     |  |          |                 |            |




AB Title diaryl ethers I [wherein X1-X10 = independently C, CH, or N; provided that each of rings A or B has no more than 2 N atoms; E = O or NH; R1 and R2 = independently H or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (alkyl)aryl, (aryl)heterocyclyl, (cyclo)alkylheterocyclyl, (cyclo)alkanoylalkyl, aroylalkyl, aryloxyalkyl, benzhydryl, bicyclyl(alkyl), benzoyl(alkyl), alkoxyalkyl, alkoxycarbonyl, (aryl)alkylsulfonyl, heterocyclylalkylsulfonyl, cycloalkylalkyl, carboxyalkyl, carbamoylalkyl, etc.; R3 and R3' = independently H, alkyl, alkenyl, alkynyl, (alkyl)aryl, or alkylcycloalkyl; R4 and R5 = independently H, (halo)alkyl, alkenyl, alkynyl, alkoxy(halo)alkyl, thioalkyl, halo, aryl(alkyl), alkanoyl, alkoxycarbonyl, aminoalkyl, cycloalkylalkyl, etc.; R6 and R7 = independently H, (cyclo)alkyl, alkenyl, alkynyl, alkanoyl, OH, alkoxy, (aryl)alkylsulfonyl, heterocyclylalkylsulfonyl, aryl(alkyl), carbamoyl(alkyl), etc.; m = 1-3; n = 0-3; p = 0-3; or pharmaceutically acceptable salts, solvates, enantiomers, racemates, diastereomers, or mixts. thereof] were prepared as  $\mu$ -,  $\kappa$ -, and  $\delta$ -opioid receptor antagonists. For example, reductive amination of 6-(2-fluoro-4-formylphenoxy)nicotinamide and 3-methylbutylamine provided II (99%). The latter inhibited ex vivo binding of [3H]-diprenorphine in rat striatum/nucleus accumbens by >65% at a concentration of 7 mg/kg. In an acute feeding rat obesity assay, II suppressed opioid receptors at a dose of 0.3  $\mu$ g/kg. In addition, diet-induced obese rats achieved an energy balance (caloric intake minus utilization) of -81 kcal/kg/day upon administration of 0.3 mg/kg p.o. of II in an indirect calorimetry assay. Thus, I and their pharmaceutical compns. are useful for the treatment, prevention, or amelioration of obesity and related diseases.

IT 676496-49-4P, 5-[4-[(3-Methylbutylamino)methyl]phenoxy]pyridine-2-carboxamide 676497-19-1P, 6-[2-Methoxy-4-[(4-methylpentylamino)methyl]phenoxy]nicotinamide 676497-85-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of (aryloxy)nicotinamides and analogs as opioid receptor antagonist for treatment of obesity and related conditions)


RN 676496-49-4 CAPLUS

CN 2-Pyridinecarboxamide, 5-[4-[[ (3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676497-19-1 CAPLUS


CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[ (4-methylpentyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676497-85-1 CAPLUS  
 CN Carbamic acid, [[4-[[5-(aminocarbonyl)-2-pyridinyl]oxy]-3-chlorophenyl]methyl](3,3-dimethylbutyl)-, 1,1-dimethylethyl ester (9CI)  
 (CA INDEX NAME)




IT 676494-38-5P, 6-[2-Methyl-4-[(3-methylbutylamino)methyl]phenoxy]nicotinamide 676494-39-6P, 6-[2-Fluoro-4-[[3-methylbutyl)amino]methyl]phenoxy]nicotinamide 676501-07-8P, 5-[4-[[4,4-Dimethylpentyl)amino]methyl]-2-fluorophenoxy]pyridine-2-carboxamide  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (opioid receptor antagonist; preparation of (aryloxy)nicotinamides and analogs as opioid receptor antagonist for treatment of obesity and related conditions)  
 RN 676494-38-5 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[2-methyl-4-[(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676494-39-6 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[[3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676501-07-8 CAPLUS  
 CN 2-Pyridinecarboxamide, 5-[4-[[4,4-dimethylpentyl)amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)



IT 676494-40-9P, 6-[2-Chloro-4-[(3-methylbutylamino)methyl]phenoxy]nicotinamide 676494-41-0P, 6-[2-Ethoxy-4-[(3-methylbutylamino)methyl]phenoxy]nicotinamide 676494-49-8P, 6-[4-[(3,3-Dimethylbutylamino)methyl]-2-methylphenoxy]nicotinamide 676494-51-2P, 6-[4-[(Butylamino)methyl]-2-methylphenoxy]nicotinamide 676494-52-3P, 6-[2-Methyl-4-[[methyl(3-methylbutyl)amino)methyl]phenoxy]nicotinamide 676494-82-9P, 6-[4-[(3-Phenylpropylamino)methyl]phenoxy]nicotinamide 676494-83-0P, 6-[4-[(3,3-Diphenylpropylamino)methyl]phenoxy]nicotinamide 676494-84-1P, 6-[4-[(3,3-Dimethylbutylamino)methyl]phenoxy]nicotinamide 676494-92-1P, 6-[4-[(3-Methylbutylamino)methyl]phenoxy]nicotinamide 676494-95-4P, 6-[4-[(6-Hydroxyhexylamino)methyl]phenoxy]nicotinamide 676494-97-6P, 6-[4-[(Decylamino)methyl]phenoxy]nicotinamide 676495-03-7P, 6-[4-[[[3-(2-Methylpiperidin-1-yl)propyl]amino)methyl]phenoxy]nicotinamide 676495-06-0P, 6-[4-[(Pentylamino)methyl]phenoxy]nicotinamide 676495-11-7P, 4-[4-[(Pentylamino)methyl]phenoxy]benzamide 676495-42-4P, 6-[4-[(3-Methylbutylamino)methyl]-2-ethoxyphenoxy]nicotinamide methanesulfonate 676495-43-5P, 6-[4-[(Butylamino)methyl]-2-ethoxyphenoxy]nicotinamide 676496-50-7P, 5-[4-[(3-Methylbutylamino)methyl]phenoxy]pyridine-2-carboxamide methanesulfonate 676496-52-9P, 5-[2-Methyl-4-[(3-methylbutylamino)methyl]phenoxy]pyridine-2-carboxamide methanesulfonate 676496-55-2P, 5-[2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy]pyridine-2-carboxamide methanesulfonate 676496-80-3P, 5-[2-Fluoro-4-[(3-methylbutylamino)methyl]phenoxy]pyridine-2-carboxamide methanesulfonate 676496-84-7P, 5-[2-Methyl-4-[(3-methylbutylamino)methyl]phenoxy]pyrazine-2-carboxamide methanesulfonate 676496-88-1P, 5-[2-Fluoro-4-[(pentylamino)methyl]phenoxy]pyridine-2-carboxamide 676496-93-8P, 5-[2-Chloro-4-[(3-methylbutylamino)methyl]phenoxy]pyridine-2-carboxamide 676496-96-1P, 5-[2-Chloro-4-[(pentylamino)methyl]phenoxy]pyridine-2-carboxamide 676496-99-4P, 6-[2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy]nicotinamide 676497-06-6P, 6-[2-Methoxy-4-[(pentylamino)methyl]phenoxy]nicotinamide 676497-10-2P, 6-[4-[(3,3-Dimethylbutylamino)methyl]-2-methoxyphenoxy]nicotinamide 676497-12-4P, 6-[4-[(Butylamino)methyl]-2-methoxyphenoxy]nicotinamide 676497-18-0P, 6-[4-[(Hexylamino)methyl]-2-methoxyphenoxy]nicotinamide 676497-20-4P, 6-[2-Methoxy-4-[(4-methylpentylamino)methyl]phenoxy]nicotinamide methanesulfonate 676497-24-8P, 5-[4-[(3,3-Dimethylbutylamino)methyl]-2-methylphenoxy]pyrazine-2-carboxamide 676497-25-9P, 5-[4-[(3-Methylbutylamino)methyl]phenoxy]pyrazine-2-carboxamide 676497-29-3P, 5-[4-[(3,3-Dimethylbutylamino)methyl]phenoxy]pyrazine-2-carboxamide 676497-67-9P, 6-[2-Fluoro-4-[[3-methylbutyl(pentyl)amino)methyl]phenoxy]nicotinamide 676497-68-0P, 6-[2-Fluoro-4-[[N-(3-methylbutyl)-N-propylamino)methyl]phenoxy]nicotinamide 676497-69-1P, 6-[4-[[Bis(3-methylbutyl)amino)methyl]-2-fluorophenoxy]nicotinamide 676497-86-2P, 6-[2-Chloro-4-[(3,3-dimethylbutylamino)methyl]phenoxy]nicotinamide 676498-03-6P,

4-[2-Methyl-4-[(3-methylbutylamino)methyl]phenoxy]benzamide  
 676498-08-1P, 4-[3-Chloro-4-[(3-methylbutylamino)methyl]phenoxy]be  
 nzamide 676498-13-8P, 4-[2-Ethoxy-4-[(3-  
 methylbutylamino)methyl]phenoxy]benzamide 676499-89-1P,  
 6-[4-[[ (3-Methylbutyl) (cyclopropylmethyl) amino]methyl]-2-  
 fluorophenoxy]nicotinamide 676499-90-4P, 6-[4-[[ (3-  
 Methylbutyl) (cyclohexylmethyl) amino]methyl]-2-fluorophenoxy]nicotinamide  
 676500-01-9P, 6-[2-Fluoro-4-[(propylamino)methyl]phenoxy]nicotinam  
 ide 676500-02-0P, 6-[2-Fluoro-4-[(hexylamino)methyl]phenoxy]nico  
 tinamide 676500-23-5P, 4-[2-Chloro-4-[(3,3-  
 dimethylbutylamino)methyl]phenoxy]benzamide 676500-24-6P,  
 4-[2-Chloro-4-[(3-methylbutylamino)methyl]phenoxy]benzamide  
 676500-25-7P, 6-[4-[[ (3-Methylbutyl) amino]methyl]phenoxy]nicotinam  
 ide hydrochloride 676500-26-8P, 4-[2-Chloro-4-  
 [(pentylamino)methyl]phenoxy]benzamide 676500-38-2P,  
 6-[2,3-Difluoro-4-[(pentylamino)methyl]phenoxy]nicotinamide  
 676500-42-8P, 6-[4-[(3,3-Dimethylbutylamino)methyl]-2-fluoro-6-  
 methoxyphenoxy]nicotinamide 676500-45-1P, 6-[4-[(3,3-  
 Dimethylbutylamino)methyl]-2,6-difluorophenoxy]nicotinamide  
 676500-48-4P, 6-[2,6-Difluoro-4-[(3-methylbutylamino)methyl]phenox  
 y]nicotinamide 676500-49-5P, 6-[2,3,6-Trifluoro-4-[(3-  
 methylbutylamino)methyl]phenoxy]nicotinamide 676500-65-5P,  
 5-[2-Methoxy-4-[(pentylamino)methyl]phenoxy]pyrazine-2-carboxamide  
 676500-73-5P, 6-[2-Methoxy-4-[(propylamino)methyl]phenoxy]nicotina  
 mide methanesulfonate 676500-81-5P, 6-[4-[(Heptylamino)methyl]-2-  
 methoxyphenoxy]nicotinamide methanesulfonate 676500-85-9P,  
 6-[2-Methoxy-4-[(3-methoxypropylamino)methyl]phenoxy]nicotinamide  
 methanesulfonate 676500-87-1P, 6-[4-[(3-  
 Ethoxypropylamino)methyl]-2-methoxyphenoxy]nicotinamide methanesulfonate  
 676500-89-3P, 6-[4-[(3-Isopropoxypropylamino)methyl]-2-  
 methoxyphenoxy]nicotinamide methanesulfonate 676500-93-9P,  
 6-[4-[(3-Ethylpentylamino)methyl]-2-methoxyphenoxy]nicotinamide  
 methanesulfonate 676500-98-4P, 6-[2-Methoxy-4-[[[3-(morpholin-4-  
 yl)propyl]amino]methyl]phenoxy]nicotinamide methanesulfonate  
 676500-99-5P, 5-[4-[(3,3-Dimethylbutylamino)methyl]-2-  
 fluorophenoxy]pyrazine-2-carboxamide 676501-05-6P,  
 5-[2-Fluoro-4-[(4-methylpentylamino)methyl]phenoxy]pyridine-2-carboxamide  
 676501-06-7P, 5-[4-[(3,3-Dimethylbutylamino)methyl]-2-  
 fluorophenoxy]pyridine-2-carboxamide 676501-08-9P,  
 5-[4-[(3-Ethylpentylamino)methyl]-2-fluorophenoxy]pyridine-2-carboxamide  
 676501-12-5P, 5-[2-Fluoro-4-[(pentylamino)methyl]phenoxy]pyrazine-  
 2-carboxamide 676501-13-6P, 5-[4-[(4,4-  
 Dimethylpentylamino)methyl]-2-fluorophenoxy]pyrazine-2-carboxamide  
 676501-14-7P, 5-[4-[(3-Ethylpentylamino)methyl]-2-  
 fluorophenoxy]pyrazine-2-carboxamide 676501-19-2P,  
 5-[2-Fluoro-4-[(hexylamino)methyl]phenoxy]pyrazine-2-carboxamide  
 676501-21-6P, 5-[2-Fluoro-4-[(3-isopropoxypropylamino)methyl]pheno  
 xy]pyrazine-2-carboxamide 676501-32-9P, 5-[2-Methoxy-4-[(3-  
 methylbutylamino)methyl]phenoxy]pyrazine-2-carboxamide  
 676501-33-0P, 5-[2-Methoxy-4-[(4-methylpentylamino)methyl]phenoxy]  
 pyrazine-2-carboxamide 676501-34-1P, 5-[4-[(3,3-  
 Dimethylbutylamino)methyl]-2-methoxyphenoxy]pyrazine-2-carboxamide  
 676501-35-2P, 5-[4-[(4,4-Dimethylpentylamino)methyl]-2-  
 methoxyphenoxy]pyrazine-2-carboxamide 676501-36-3P,  
 5-[4-[(3-Ethylpentylamino)methyl]-2-methoxyphenoxy]pyrazine-2-carboxamide  
 676501-39-6P, 5-[2-Methoxy-4-[(3-methoxypropylamino)methyl]phenoxy  
 ]pyrazine-2-carboxamide 676501-81-8P, 5-[2-Fluoro-4-[(3-  
 methylbutylamino)methyl]phenoxy]pyrazine-2-carboxamide  
 676501-82-9P, 6-[2-Methyl-4-[(3-methylbutylamino)methyl]phenoxy]ni  
 cotinamide methanesulfonate


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(opioid receptor antagonist; preparation of (aryloxy)nicotinamides and analogs as opioid receptor antagonist for treatment of obesity and related conditions)


RN 676494-40-9 CAPLUS

CN 3-Pyridinecarboxamide, 6-[2-chloro-4-[[ (3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-41-0 CAPLUS

CN 3-Pyridinecarboxamide, 6-[2-ethoxy-4-[[ (3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-49-8 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[ (3,3-dimethylbutyl)amino]methyl]-2-methylphenoxy]- (CA INDEX NAME)




RN 676494-51-2 CAPLUS


CN 3-Pyridinecarboxamide, 6-[4-[(butylamino)methyl]-2-methylphenoxy]- (CA INDEX NAME)




RN 676494-52-3 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[2-methyl-4-[[methyl(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676494-82-9 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[4-[[[3-phenylpropyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-83-0 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[4-[[[3,3-diphenylpropyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-84-1 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[4-[[[3,3-dimethylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)







RN 676494-92-1 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[4-[[3-methylbutyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-95-4 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[4-[[6-hydroxyhexyl]amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676494-97-6 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[4-[(decylamino)methyl]phenoxy]- (CA INDEX NAME)




RN 676495-03-7 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[4-[[3-(2-methyl-1-piperidiny)propyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676495-06-0 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[4-[(pentylamino)methyl]phenoxy]- (CA INDEX NAME)

NAME)



RN 676495-11-7 CAPLUS

CN Benzamide, 4-[4-[(pentylamino)methyl]phenoxy]- (CA INDEX NAME)




RN 676495-42-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-[2-ethoxy-4-[[ (3-methylbutyl)amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676494-41-0


CMF C20 H27 N3 O3



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 676495-43-5 CAPLUS


CN 3-Pyridinecarboxamide, 6-[4-[(butylamino)methyl]-2-ethoxyphenoxy]- (CA INDEX NAME)



RN 676496-50-7 CAPLUS  
 CN 2-Pyridinecarboxamide, 5-[4-[[3-methylbutyl]amino]methyl]phenoxy]-,  
 monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676496-49-4  
 CMF C18 H23 N3 O2



CM 2


CRN 75-75-2  
 CMF C H4 O3 S



RN 676496-52-9 CAPLUS  
 CN 2-Pyridinecarboxamide, 5-[2-methyl-4-[[3-methylbutyl]amino]methyl]phenoxy]-,  
 monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 676496-51-8  
 CMF C19 H25 N3 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 676496-55-2 CAPLUS

CN 2-Pyridinecarboxamide, 5-[2-methoxy-4-[[ (3-methylbutyl) amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676496-54-1


CMF C19 H25 N3 O3



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 676496-80-3 CAPLUS

CN 2-Pyridinecarboxamide, 5-[2-fluoro-4-[[ (3-methylbutyl) amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676496-79-0


CMF C18 H22 F N3 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 676496-84-7 CAPLUS

CN Pyrazinecarboxamide, 5-[2-methyl-4-[(3-methylbutyl)amino]methoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676496-83-6


CMF C18 H24 N4 O2



CM 2


CRN 75-75-2

CMF C H4 O3 S




RN 676496-88-1 CAPLUS

CN 2-Pyridinecarboxamide, 5-[2-fluoro-4-[(pentylamino)methyl]phenoxy]- (CA INDEX NAME)




RN 676496-93-8 CAPLUS

CN 2-Pyridinecarboxamide, 5-[2-chloro-4-[[3-methylbutyl]amino]methoxy]pyridine-3-carboxamide, 5-[2-chloro-4-[[3-methylbutyl]amino]methoxy]pyridine-3-carboxamide (CA INDEX NAME)




RN 676496-96-1 CAPLUS

CN 2-Pyridinecarboxamide, 5-[2-chloro-4-[(pentylamino)methyl]phenoxy]pyridine-3-carboxamide, 5-[2-chloro-4-[(pentylamino)methyl]phenoxy]pyridine-3-carboxamide (CA INDEX NAME)




RN 676496-99-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[3-methylbutyl]amino]methoxy]pyridine-3-carboxamide, 6-[2-methoxy-4-[[3-methylbutyl]amino]methoxy]pyridine-3-carboxamide (CA INDEX NAME)




RN 676497-06-6 CAPLUS


CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[(pentylamino)methyl]phenoxy]pyridine-3-carboxamide, 6-[2-methoxy-4-[(pentylamino)methyl]phenoxy]pyridine-3-carboxamide (CA INDEX NAME)




RN 676497-10-2 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[4-[(3,3-dimethylbutyl)amino]methyl]-2-methoxyphenoxy]- (CA INDEX NAME)



RN 676497-12-4 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[4-[(butylamino)methyl]-2-methoxyphenoxy]- (CA INDEX NAME)



RN 676497-18-0 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[4-[(hexylamino)methyl]-2-methoxyphenoxy]- (CA INDEX NAME)




RN 676497-20-4 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[(4-methylpentyl)amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676497-19-1


CMF C20 H27 N3 O3



CM 2


CRN 75-75-2

CMF C H4 O3 S




RN 676497-24-8 CAPLUS

CN Pyrazinecarboxamide, 5-[4-[[[(3,3-dimethylbutyl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 676497-25-9 CAPLUS


CN Pyrazinecarboxamide, 5-[4-[[[(3-methylbutyl)amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 676497-29-3 CAPLUS


CN Pyrazinecarboxamide, 5-[4-[[[(3,3-dimethylbutyl)amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)






RN 676497-67-9 CAPLUS

CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[[3-methylbutyl]pentylamino]methyl]phenoxy]- (CA INDEX NAME)




RN 676497-68-0 CAPLUS

CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[[3-methylbutyl]propylamino]methyl]phenoxy]- (CA INDEX NAME)




RN 676497-69-1 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[bis(3-methylbutyl)amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)




RN 676497-86-2 CAPLUS


CN 3-Pyridinecarboxamide, 6-[2-chloro-4-[[3,3-dimethylbutyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676498-03-6 CAPLUS  
 CN Benzamide, 4-[2-methyl-4-[[3-methylbutyl]amino]methyl]phenoxy]- (CA INDEX NAME)





RN 676498-08-1 CAPLUS  
 CN Benzamide, 4-[3-chloro-4-[[3-methylbutyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676498-13-8 CAPLUS  
 CN Benzamide, 4-[2-ethoxy-4-[[3-methylbutyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676499-89-1 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[4-[[3-methylbutyl]amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)




RN 676499-90-4 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[4-[[ (cyclohexylmethyl) (3-methylbutyl) amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)



RN 676500-01-9 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[(propylamino)methyl]phenoxy]- (CA INDEX NAME)




RN 676500-02-0 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[(hexylamino)methyl]phenoxy]- (CA INDEX NAME)




RN 676500-23-5 CAPLUS  
 CN Benzamide, 4-[2-chloro-4-[[ (3,3-dimethylbutyl) amino]methyl]phenoxy]- (CA

INDEX NAME)




RN 676500-24-6 CAPLUS

CN Benzamide, 4-[2-chloro-4-[(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676500-25-7 CAPLUS


CN 3-Pyridinecarboxamide, 6-[4-[(3-methylbutyl)amino]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 676500-26-8 CAPLUS

CN Benzamide, 4-[2-chloro-4-[(pentylamino)methyl]phenoxy]- (CA INDEX NAME)




RN 676500-38-2 CAPLUS

CN 3-Pyridinecarboxamide, 6-[2,3-difluoro-4-[(pentylamino)methyl]phenoxy]- (CA INDEX NAME)




RN 676500-42-8 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[3,3-dimethylbutyl]amino]methyl]-2-fluoro-6-methoxyphenoxy]- (CA INDEX NAME)




RN 676500-45-1 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[3,3-dimethylbutyl]amino]methyl]-2,6-difluorophenoxy]- (CA INDEX NAME)




RN 676500-48-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-[2,6-difluoro-4-[[3-methylbutyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676500-49-5 CAPLUS

CN 3-Pyridinecarboxamide, 6-[2,3,6-trifluoro-4-[[3-methylbutyl]amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676500-65-5 CAPLUS

CN Pyrazinecarboxamide, 5-[2-methoxy-4-[(pentylamino)methyl]phenoxy]- (9CI)  
(CA INDEX NAME)




RN 676500-73-5 CAPLUS

CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[(propylamino)methyl]phenoxy]-,  
monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676500-72-4


CMF C17 H21 N3 O3



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 676500-81-5 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[(heptylamino)methyl]-2-methoxyphenoxy]-,  
monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676500-80-4


CMF C21 H29 N3 O3



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 676500-85-9 CAPLUS

CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[(3-methoxypropyl)amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676500-84-8


CMF C18 H23 N3 O4



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 676500-87-1 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[ (3-ethoxypropyl)amino]methyl]-2-methoxyphenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676500-86-0


CMF C19 H25 N3 O4



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 676500-89-3 CAPLUS

CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[3-(1-methylethoxy)propyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676500-88-2

CMF C20 H27 N3 O4






CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 676500-93-9 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[ (3-ethylpentyl)amino)methyl]-2-methoxyphenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676500-92-8


CMF C21 H29 N3 O3



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 676500-98-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[3-(4-morpholinyl)propyl]amino)methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676500-97-3


CMF C21 H28 N4 O4



CM 2


CRN 75-75-2

CMF C H4 O3 S




RN 676500-99-5 CAPLUS

CN Pyrazinecarboxamide, 5-[4-[[3-(3,3-dimethylbutyl)amino]methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 676501-05-6 CAPLUS

CN 2-Pyridinecarboxamide, 5-[2-fluoro-4-[[4-methylpentyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676501-06-7 CAPLUS


CN 2-Pyridinecarboxamide, 5-[4-[[3-(3,3-dimethylbutyl)amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)




RN 676501-08-9 CAPLUS  
 CN 2-Pyridinecarboxamide, 5-[4-[[3-ethylpentyl]amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)




RN 676501-12-5 CAPLUS  
 CN Pyrazinecarboxamide, 5-[2-fluoro-4-[(pentylamino)methyl]phenoxy]- (9CI)  
 (CA INDEX NAME)



RN 676501-13-6 CAPLUS  
 CN Pyrazinecarboxamide, 5-[4-[[4,4-dimethylpentyl]amino]methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 676501-14-7 CAPLUS  
 CN Pyrazinecarboxamide, 5-[4-[[3-ethylpentyl]amino]methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)




RN 676501-19-2 CAPLUS

CN Pyrazinecarboxamide, 5-[2-fluoro-4-[(hexylamino)methyl]phenoxy]- (9CI)  
(CA INDEX NAME)




RN 676501-21-6 CAPLUS

CN Pyrazinecarboxamide, 5-[2-fluoro-4-[[[3-(1-methylethoxy)propyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 676501-32-9 CAPLUS

CN Pyrazinecarboxamide, 5-[2-methoxy-4-[[[3-methylbutyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 676501-33-0 CAPLUS

CN Pyrazinecarboxamide, 5-[2-methoxy-4-[[[4-methylpentyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 676501-34-1 CAPLUS

CN    Pyrazinecarboxamide, 5-[4-[[ (3,3-dimethylbutyl)amino]methyl]-2-methoxyphenoxy]- (9CI)    (CA INDEX NAME)




RN 676501-35-2 CAPLUS

CN    Pyrazinecarboxamide, 5-[4-[[ (4,4-dimethylpentyl)amino]methyl]-2-methoxyphenoxy]- (9CI)    (CA INDEX NAME)




RN 676501-36-3 CAPLUS

CN     Pyrazinecarboxamide, 5-[4-[[ (3-ethylpentyl) amino]methyl]-2-methoxyphenoxy]-  
        (9CI)     (CA INDEX NAME)




RN 676501-39-6 CAPLUS

CN    Pyrazinecarboxamide, 5-[2-methoxy-4-[[ (3-methoxypropyl) amino]methyl]phenoxy]- (9CI)    (CA INDEX NAME)



RN 676501-81-8 CAPLUS

CN Pyrazinecarboxamide, 5-[2-fluoro-4-[(3-methylbutyl)amino]methyl]phenoxy]-  
(9CI) (CA INDEX NAME)




RN 676501-82-9 CAPLUS

CN 3-Pyridinecarboxamide, 6-[2-methyl-4-[(3-methylbutyl)amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676494-38-5


CMF C19 H25 N3 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S



REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 13:41:16 ON 26 DEC 2007  
FILE 'CAPLUS' ENTERED AT 13:41:16 ON 26 DEC 2007  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)  
COST IN U.S. DOLLARS

|                     | SINCE FILE | TOTAL   |
|---------------------|------------|---------|
|                     | ENTRY      | SESSION |
| FULL ESTIMATED COST | 25.68      | 199.10  |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL   |
|--|------------|---------|
|  | ENTRY      | SESSION |
| CA SUBSCRIBER PRICE                        | -2.34      | -2.34   |

=> file registry  
COST IN U.S. DOLLARS

|                     | SINCE FILE | TOTAL   |
|---------------------|------------|---------|
|                     | ENTRY      | SESSION |
| FULL ESTIMATED COST | 25.68      | 199.10  |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL   |
|--|------------|---------|
|  | ENTRY      | SESSION |
| CA SUBSCRIBER PRICE                        | -2.34      | -2.34   |

FILE 'REGISTRY' ENTERED AT 13:41:27 ON 26 DEC 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 DEC 2007 HIGHEST RN 959463-53-7  
DICTIONARY FILE UPDATES: 25 DEC 2007 HIGHEST RN 959463-53-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10 series\10526960\10526960b.str



```

chain nodes :
7 16 17 18 19 20 21 22 23 24 27 28
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13
chain bonds :
1-24 2-28 3-16 5-27 6-7 7-8 11-21 16-17 17-18 18-19 19-20 21-22 21-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
exact/norm bonds :
1-24 2-28 3-16 5-27 6-7 7-8 8-9 8-13 9-10 10-11 11-12 11-21 12-13
16-17 17-18 18-19 19-20 21-22 21-23
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

```

G1:N,CH

G2:X,O,CH3,H

G3:H,X

G4:H,X,O

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:CLASS
22:CLASS 23:CLASS 24:CLASS 27:CLASS 28:CLASS

```




L5            STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5                    STR



G1 N,CH

G2 X,O,Me,H

G3 H,X

G4 H,X,O

Structure attributes must be viewed using STN Express query preparation.

=> s 15 full

FULL SEARCH INITIATED 13:41:49 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED -        23372 TO ITERATE

100.0% PROCESSED        23372 ITERATIONS

95 ANSWERS

SEARCH TIME: 00.00.01

L6                    95 SEA SSS FUL L5

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

371.20

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-2.34

FILE 'CAPLUS' ENTERED AT 13:41:55 ON 26 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications.  
The CA Lexicon is the copyrighted intellectual property of the  
American Chemical Society and is provided to assist you in searching  
databases on STN. Any dissemination, distribution, copying, or storing  
of this information, without the prior written consent of CAS, is  
strictly prohibited.

FILE COVERS 1907 - 26 Dec 2007 VOL 147 ISS 26  
FILE LAST UPDATED: 25 Dec 2007 (20071225/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 16

L7 3 L6

=> log hold

|  |            |         |
|--|------------|---------|
| COST IN U.S. DOLLARS                       | SINCE FILE | TOTAL   |
|  | ENTRY      | SESSION |
| FULL ESTIMATED COST                        | 0.47       | 371.67  |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL   |
|  | ENTRY      | SESSION |
| CA SUBSCRIBER PRICE                        | 0.00       | -2.34   |

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 13:42:04 ON 26 DEC 2007